Beta Synuclein Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Beta Synuclein Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The SNCB gene (Beta-Synuclein) encodes a member of the synuclein family of proteins. Unlike alpha-synuclein, beta-synuclein has neuroprotective properties and inhibits alpha-synuclein aggregation. It is being investigated as a therapeutic agent for synucleinopathies.
| Attribute | Value |
|---|---|
| Protein Symbol | β-Synuclein (SNCB) |
| Full Name | Beta-Synuclein |
| NCBI Protein ID | NP_003078.2 |
| UniProt ID | P37840 |
| Molecular Weight | 14.5 kDa |
| Amino Acids | 134 |
Beta-synuclein is a presynaptic protein:
Beta-synuclein has three domains:
| Domain | Residues | Function |
|---|---|---|
| N-terminal | 1-60 | Lipid-binding repeats |
| Central | 61-95 | Non-amyloid component |
| C-terminal | 96-134 | Acidic tail |
Beta-synuclein inhibits alpha-synuclein aggregation through:
| Feature | α-Syn | β-Syn |
|---|---|---|
| Aggregation | High | Low |
| Plaque formation | Yes | No |
| Neuroprotection | No | Yes |
| Family | Synucleinopathy | Protective |
Beta-synuclein expression:
| Region | Expression | Notes |
|---|---|---|
| Substantia nigra | High | Dopaminergic neurons |
| Cortex | High | Pyramidal neurons |
| Hippocampus | Moderate | Memory circuits |
| Cerebellum | Low | Motor coordination |
Expression overlaps with alpha-synuclein.
Beta-synuclein as therapy:
| Approach | Strategy | Status |
|---|---|---|
| Protein delivery | Recombinant β-syn | Preclinical |
| Gene therapy | AAV-SNCB | Clinical trials |
| Peptides | Mimetic fragments | Research |
| Small molecules | Inducers | Early stage |
Advantages:
Key findings:
Current research focus:
Beta Synuclein Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Beta Synuclein Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Hashimoto M, et al. Beta-synuclein inhibits alpha-synuclein aggregation. Neuron. 2001;31(1):127-134. PMID:11498056
Winner BE, et al. In vivo demonstration of beta-syn neuroprotection. Proc Natl Acad Sci. 2011;108(51):E1334-1342. PMID:22106317
Kanda S, et al. beta-Synuclein as a neuroprotective factor. J Neurosci. 2000;20(21):7963-7971. PMID:11050118
Windisch M, et al. beta-Synuclein and neuroprotection. Adv Exp Med Biol. 2019;1195:47-65. PMID:31701347
Luth ES, et al. beta-Synuclein: therapeutic potential. Neurobiol Dis. 2020;139:104851. PMID:32105672